CD123
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
CD123
May 1, 2024, 10:13 |
Blog
Jayastu Senapati: Talk on Blastic plasmacytoid dendritic cell neoplasm
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center shared a post on…
Apr 21, 2024, 21:27 |
Drugs
Hagop Kantarjian: We review the evidence leading to Tagraxofusp approval as first in class CD123-directed drug which has changed the field of BPDCN
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: “Tazgraxofusp is…
Apr 15, 2024, 12:42 |
Blog
Naveen Pemmaraju: Our collaboration with Dr Gabe Mannis and team in BPDCN
Naveen Pemmaraju shared a post on X: "Our collaboration with/Dr Gabe Mannis and team with…
Jun 9, 2023, 02:54 |
Insight
The field of BPDCN is rapidly evolving - Hagop Kantarjian
The field of BPDCN is rapidly evolving. Our new article by Dr. Pemmaraju highlights the…
All:
4
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube